TargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease
van Dyck C, Kahl A, Abelian G, Donovan M, Ahuja M, Watson D, Ossenkoppele R, Iwatsubo T, Hansson O. TargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease. Alzheimer's & Dementia 2024, 20: e094677. PMCID: PMC11712654, DOI: 10.1002/alz.094677.Peer-Reviewed Original ResearchMicrotubule binding regionTau monoclonal antibodiesTau speciesTau proteinMicrotubule-associated protein tauNeurotoxic tau speciesTau-induced neurotoxicityIntracellular neurofibrillary tanglesCell surface receptorsAD clinical progressionProtein tauNeurofibrillary tanglesBinding regionMonoclonal antibodiesTau transmissionSynaptic lossExtracellular accumulationSurface receptorsTau concentrationsCerebrospinal fluid correlateAlzheimer's diseaseTauIn vitro activity studiesSelf-associationSpecies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply